54.88
2.04 (3.86%)
| Previous Close | 52.84 |
| Open | 52.80 |
| Volume | 1,726,056 |
| Avg. Volume (3M) | 1,492,587 |
| Market Cap | 6,576,179,200 |
| Price / Sales | 13.14 |
| Price / Book | 24.35 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2026 |
| Diluted EPS (TTM) | -2.55 |
| Total Debt/Equity (MRQ) | 20.22% |
| Current Ratio (MRQ) | 10.25 |
| Operating Cash Flow (TTM) | -229.84 M |
| Levered Free Cash Flow (TTM) | -134.32 M |
| Return on Assets (TTM) | -50.15% |
| Return on Equity (TTM) | -106.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Scholar Rock Holding Corporatio | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -3.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.13 |
|
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.35% |
| % Held by Institutions | 118.63% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BUROW KRISTINA | - | 52.84 | -3,053 | -161,321 |
| FLIER JEFFREY S. | - | 52.84 | -3,053 | -161,321 |
| GILMAN MICHAEL | - | 52.84 | -2,544 | -134,425 |
| PENG KATIE | - | 52.84 | -5,446 | -287,767 |
| REED JOSHUA | - | 52.84 | -3,053 | -161,321 |
| Aggregate Net Quantity | -17,149 | |||
| Aggregate Net Value ($) | -906,153 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 52.84 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PENG KATIE | Director | 01 Jul 2026 | Sell (-) | 5,446 | 52.84 | 287,767 |
| REED JOSHUA | Director | 01 Jul 2026 | Sell (-) | 3,053 | 52.84 | 161,321 |
| BUROW KRISTINA | Director | 01 Jul 2026 | Sell (-) | 3,053 | 52.84 | 161,321 |
| FLIER JEFFREY S. | Director | 01 Jul 2026 | Sell (-) | 3,053 | 52.84 | 161,321 |
| GILMAN MICHAEL | Director | 01 Jul 2026 | Sell (-) | 2,544 | 52.84 | 134,425 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |